TerminatedPhase 2NCT02528318

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Studying Neonatal acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Steve Simonson, MD
Windtree Therapeutics
Intervention
Lucinactant for inhalation(combination_product)
Enrollment
48 target
Eligibility
All sexes
Timeline
20152017

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02528318 on ClinicalTrials.gov

Other trials for Neonatal acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Neonatal acute respiratory distress syndrome

← Back to all trials